Key result
Current non-pharmacological and pharmacological prevention strategies for hypertension-related disorders incur enormous public health costs without demonstrating sufficient cost-benefit improvements.
Why the study?
Cardiovascular disorders related to hypertension cause high rates of fatal and non-fatal events, but large-scale trials do not support effective benefits from current prevention strategies despite high public health costs.
Answers are grounded in this paper and cite their sources.
The review highlights the need for better quantitative measures to improve the cost-benefit ratio of hypertension management strategies in public health.
Epidemiological surveys demonstrate undoubtedly that cardiovascular disorders caused or associated with hypertension are at a high risk of non-fatal or fatal events and occurring with a great rate. Ischaemic heart disease with effort angina and myocardial infarction, often unrecognized myocardial infarction, stroke and transient ischaemic attack may be observed more frequently than other cardiovascular disorders in hypertensive patients. Large-scale trials do not support the hypothesis that effective benefits are reached by current non-pharmacological or pharmacological prevention which need enormous costs to public health. Lowering blood pressure is the main target to reach in an attempt to reduce cardiovascular complications in hypertensive patients. Therefore, the costs-benefit ratio, which estimates public health costs, needs yet marked improvement since the public health expenses are heaviest with results that do not support the economic effort. Statistically, quantitative measures to modify the current regimen need to better evaluate both public health costs and reached benefits.
No takes yet. Share an insight, caveat, or question.
Leone et al. (2011) conducted a review in Hypertension-related disorders. Current non-pharmacological and pharmacological prevention strategies for hypertension-related disorders incur enormous public health costs without demonstrating sufficient cost-benefit improvements.
Synapse has enriched 10 related papers. Consider them for comparative context: